PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.45%
R&D change of 20.45% versus flat Healthcare spending. Walter Schloss would verify adequacy.
69.30%
G&A change of 69.30% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.79%
Operating expenses growth exceeding 1.5x Healthcare median of 0.54%. Jim Chanos would check for waste.
30.79%
Total costs growth exceeding 1.5x Healthcare median of 1.14%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
1.90%
D&A growth exceeding 1.5x Healthcare median of 0.97%. Jim Chanos would check for overinvestment.
-31.40%
EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-31.28%
Pre-tax income decline while Healthcare median is 0.60%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-264.58%
Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-31.28%
Net income decline while Healthcare median is 0.21%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-21.00%
EPS decline while Healthcare median is 5.08%. Seth Klarman would investigate causes.
-22.22%
Diluted EPS decline while Healthcare median is 5.00%. Seth Klarman would investigate causes.
7.78%
Share count reduction below 50% of Healthcare median of 0.20%. Jim Chanos would check for issues.
7.68%
Diluted share reduction below 50% of Healthcare median of 0.19%. Jim Chanos would check for issues.